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Abstract
Objective—To describe the occurrence of selected neurobehavioral concerns among males with 
a dystrophinopathy and explore associations with corticosteroid or supportive device use.
Method—Medical record abstraction of neurobehavioral concerns was conducted for 857 
affected males from 765 families, born since 1982 and followed through 2011, and enrolled in the 
population-based Muscular Dystrophy Surveillance, Tracking, and Research Network. Cumulative 
probabilities for attention deficit/hyperactivity disorder (ADHD), behavior problems, and 
depressed mood were calculated from Kaplan-Meier estimates for the subsample of oldest affected 
males (n=765). Hazard ratios (HRs) and 95% confidence intervals (95%CIs) for corticosteroid and 
supportive device use were estimated from Cox regression models with time-dependent 
covariates.
Results—Of the 857 affected males, 375 (44%) had at least one of the three selected 
neurobehavioral concerns; a similar percentage (45%) was found among the 765 oldest affected 
males. The estimated cumulative probabilities among these oldest affected males were 23% for 
ADHD, 43% for behavior problems, and 51% for depressed mood. Corticosteroid (HR=2.35, 
95%CI=1.75,3.16) and mobility device (HR=1.53, 95%CI=1.06,2.21) use were associated with 
behavior problems. Use of a mobility device (HR=3.53, 95%CI=2.13,5.85), but not 
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corticosteroids, was associated with depressed mood. ADHD was not significantly associated with 
corticosteroid or mobility device use. Respiratory assist device use was not examined due to low 
numbers of users prior to onset of neurobehavioral concerns.
Conclusion—Selected neurobehavioral concerns were common among males with a 
dystrophinopathy. Reported associations highlight the importance of increased monitoring of 
neurobehavioral concerns as interventions are implemented and disease progresses.
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OBJECTIVE
Duchenne and Becker muscular dystrophies, together referred to as dystrophinopathies, are 
caused by mutations in the dystrophin gene (DMD) on the X-chromosome and result in 
progressive muscle weakness.1,2 Duchenne muscular dystrophy (DMD) is the form most 
commonly diagnosed in early childhood and affects approximately 1:3500 males.2 Males 
with DMD generally require a wheelchair full-time by age 12 years and have shortened life 
expectancies, most often due to cardiac or respiratory failure. Becker muscular dystrophy 
(BMD) has a prevalence estimated at one-fifth of that reported for DMD.1 BMD has a less 
stereotyped course than DMD, and typically has later onset and more slowly progressive 
weakness, along with variable life expectancy.1,2 Recent treatments, including use of 
corticosteroids and respiratory support devices, have extended the survival of those with 
dystrophinopathies by delaying respiratory and cardiac complications.3
In addition to skeletal muscle involvement, learning disorders or cognitive impairment are 
often part of the dystrophinopathy phenotype.4–7 Among the neurobehavioral concerns 
studied, higher frequencies of ADHD,6,8,9 autism spectrum disorder,8,10–13 and obsessive-
compulsive disorder (OCD)8 have been reported for those affected with a dystrophinopathy 
compared to the general population.8,11 Other studies have reported high levels of clinically 
significant externalizing and internalizing behaviors11,13–15 and difficulties with social 
functioning11,14–16 among affected individuals. These neurobehavioral and psychosocial 
concerns have been attributed, in part, to underlying neurocognitive deficits17 and physical 
limitations that may arise with greater disease severity.11,15,18,19 Statistically significant 
associations between neurobehavioral concerns and indicators of disease progression or 
treatment have not been consistently reported.6,8,11,13,15 Most, but not all, of these studies 
were limited to males with DMD, although specific diagnostic criteria were not consistently 
defined.
Although frequent occurrences of neurobehavioral concerns are suggested, existing studies 
have methodological limitations. Many relied on convenience samples identified from 
clinics6,9,10,12–15,20 or recruited from patient support or advocacy groups,8,15 which may not 
be representative of the overall patient population. These studies were also cross-sectional, 
sampled a broad age range of patients, and many relied on behavioral checklists for self- or 
parent-report of neurobehavioral concerns.8,9,11,13,15,16,20 These methodological limitations 
make it difficult to fully evaluate frequencies of neurobehavioral concerns among those with 
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a dystrophinopathy and preclude the use of appropriate analytic methods that could provide 
more accurate frequency estimates and evaluate time-ordered associations with disease 
progression and treatments.
To complement these previous studies and address some of their limitations, we used 
surveillance data collected through the Muscular Dystrophy Surveillance, Tracking, and 
Research Network (MD STARnet)21,22 to describe frequencies of selected neurobehavioral 
concerns and associations with medical interventions among males with childhood-onset 
dystrophinopathy. MD STARnet data were collected through annual medical record 
abstraction in defined geographic areas, providing a population-based sample of those 
affected with dystrophinopathies. The findings from our study will provide clinicians and 
families with information about the risk of neurobehavioral concerns, thereby promoting 
optimal monitoring and timely management of such concerns.
METHOD
Study Population and Sample
The methods of Muscular Dystrophy Surveillance, Tracking, and Research Network (MD 
STARnet) have been described elsewhere.22 Briefly, starting in 2004, the MD STARnet 
retrospectively identified dystrophinopathy cases who were born since January 1, 1982, 
diagnosed by age 21 years, and resided in an MD STARnet site [Arizona (AZ), Colorado 
(CO), Iowa (IA), and the western part of New York State (wNY)]; Georgia (GA) and 
Hawaii (HI) joined the MD STARnet in 2005 and 2008, respectively. For each case 
identified, trained medical abstractors reviewed medical records and entered data into an 
electronic surveillance instrument. Abstracted data included sociodemographic data, clinical 
signs and symptoms, diagnostic/clinical tests, family history of dystrophinopathy, medical 
treatments received, and medical complications. Data on schooling, rehabilitation, mobility, 
and neurobehavioral concerns were also collected. Since the initiation of surveillance, all 
retrospectively identified and newly diagnosed cases were prospectively followed through 
annual medical record abstraction through December 31, 2011 (for cases ascertained before 
2011), December 31, 2012 (for cases ascertained in 2011), or until death or migration out of 
an MD STARnet site. Surveillance data collection was approved either through changes to 
existing public health surveillance regulations (CO, GA, IA, wNY) or institutional review 
board approvals (AZ, HI).
Selected clinical data abstracted were reviewed by a clinical review committee composed of 
health care providers experienced in treating individuals with dystrophinopathies and 
assigned a case status: possible, probable, definite, asymptomatic, or female.21 All possible 
cases had recorded clinical symptoms related to a dystrophinopathy and elevated creatine 
kinase. Probable cases also had an X-linked pedigree consistent with a dystrophinopathy. 
Definite cases had a confirmed DMD mutation, a muscle biopsy showing absent dystrophin, 
or an X-linked pedigree and an affected family member with a DMD mutation or diagnostic 
muscle biopsy. Cases who met criteria for definite, but did not show any clinical symptoms, 
were defined as asymptomatic. Females who were diagnosed with a dystrophinopathy 
before age 21 years and had a DMD mutation or diagnostic muscle biopsy were also 
ascertained. Each site performed quality control checks, and data with possible errors were 
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sent back to abstractors for further review.22 Data from each MD STARnet site were de-
identified and pooled into a combined database that included cases classified as definite, 
probable, and affected females from each site.
We analyzed the pooled MD STARnet surveillance dataset, version 7 (release date June, 
2012), which included 795 definite male cases, 80 probable male cases, and 9 affected 
females for a total of 884 cases. We excluded cases from Hawaii (n=18), due to restricted 
ascertainment and a limited follow-up period, and affected females (n=9), due to unique 
clinical and genetic features of females with a dystrophinopathy. The final analytic sample 
comprised 857 affected males with definite or probable dystrophinopathy from 765 families.
Neurobehavioral Concerns and Intervention
Neurobehavioral concerns documented in the medical records were entered into the 
abstraction instrument according to predefined categories of depression, behavior problems, 
ADHD, anger management, or other concerns. A text field was available to provide 
additional details about concerns listed as other. After review, the concerns listed in the 
other text field were recoded into the following selected subtypes: ADHD, behavior 
problems, or depressed mood. The final categories combined the predefined categories and 
those recoded from the other text field into the following subtypes: ADHD, behavior 
problems (conduct problems, externalizing behaviors, aggression, anger management 
issues), or depressed mood (depression, bipolar disorder). For each subtype, we also 
calculated the age at first documentation of each neurobehavioral concern.
At each annual follow-up abstraction, all medications and recommendations for and 
participation in counseling documented in the medical record were entered into the 
abstraction tool. Medications were reviewed and coded into the following classes: 
antidepressants, anticonvulsants, anxiolytics, antipsychotics, and psychostimulants. We 
coded counseling as received if documented as received at any point in time for a specific 
neurobehavioral concern. For cases where counseling was not coded as received, counseling 
was coded as none, unknown, or recommended but not started.
Sociodemographic and Disease-Related Characteristics
We included the following selected characteristics to describe cases: MD STARnet site, case 
race/ethnicity (non-Hispanic white, Hispanic, or other), and age at last health encounter. 
Data available for analysis of treatments and supportive devices included first use of: 
corticosteroids, a mobility device (wheelchair or scooter, at least part-time), and a 
respiratory support device (continuous positive airway pressure, biphasic positive airway 
pressure, tracheostomy). Data recorded for corticosteroids included date or age when first 
used, dates or ages when dosage was changed or discontinued, and reason for 
discontinuation. Data recorded for use of a mobility device or respiratory support device 
included date when first used and frequency of use.
Statistical Analysis
We conducted the analyses using Statistical Analysis Software (SAS) version 9.3 (SAS 
Institute, Cary, NC). We estimated the observed frequencies of each neurobehavioral 
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concern for the total sample of all affected males (n=857) and two subsamples selected to 
evaluate comparability of the oldest affected male sample to all dystrophinopathy cases in 
MD STARnet and other studies: 1) only the oldest affected male from each family (n=765) 
and 2) only oldest affected males who were at least 17 years of age at last follow-up 
(n=309). Descriptive statistics calculated included counts for categorical variables (i.e., MD 
STARnet site, race/ethnicity), as well as means (M), medians (Mdn), standard deviations 
(SD), and minimum and maximum (min, max) values for continuous variables (i.e., age at 
last health encounter; onset ages for each neurobehavioral concern; and onset ages for use of 
corticosteroids, a mobility device, and a respiratory support device). For reporting mental 
health interventions, males who had a single documented neurobehavioral concern (i.e., 
ADHD only, behavior problems only, or depressed mood only) or a combination of 2 or 
more concerns (e.g., ADHD plus behavior problems) were identified to allow examination 
of concern-specific interventions. Frequencies of counseling received and medication 
classes prescribed, or the combination of these interventions, were then calculated for each 
selected neurobehavioral concern.
For selected neurobehavioral concerns, we used the Kaplan-Meier method to estimate 
cumulative probabilities for each concern through age 29 for the sample of oldest affected 
males. Due to high censoring rates, mean and median survival times are not reported. To 
evaluate associations between each neurobehavioral concern and corticosteroid treatment or 
use of a supportive device, crude and adjusted hazard ratios (HR)s were estimated from Cox 
regression with time-dependent covariates. MD STARnet site was included as a fixed 
covariate in the adjusted analyses. Corticosteroid use was coded into annual variables with 
any use coded as ‘yes’ if corticosteroids were used at least one day during that year and as 
‘no use’ if there was not a single day of use documented for that year. This threshold was 
chosen because onset of behavior problems was an outcome of interest but may also be an 
indication for discontinuing steroid therapy. Time-dependent coding for use of a mobility 
device or respiratory support device were coded as ‘no use’ for each year up until the age at 
first use and as ‘yes’ for the year of first use and each year thereafter. Because the time-
dependent covariates were coded annually, specific dates were reviewed to ensure accurate 
temporal ordering was captured (e.g., onset of part-time wheelchair use did not occur after 
onset of depressed mood within the same year).
Comparative Analyses
For comparative purposes, we constructed two additional sets of analytic samples that more 
closely represented the published maximum age of risk for a specific neurobehavioral 
concern23 or the maximum age included in national studies of childhood-onset 
neurobehavioral concerns.24 For the first sample, an age of risk approach was used, whereby 
the maximum follow-up age was defined as the published maximum age of risk for a given 
neurobehavioral concern or at least 95% of the observed age distribution (i.e., up to and 
including the 14th birthday for ADHD and behavior problems, and the 19th birthday for 
depressed mood). For the second sample, a population-based approach was used to create a 
sample consistent with ages based on samples recruited for national studies of 
neurobehavioral concerns.24 The maximum age for this approach was up to and including 
the 17th birthday for each neurobehavioral concern examined. For each approach, the age at 
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final follow-up was recoded to the defined maximum age. Using onset of behavioral 
problems as an example, the age of risk approach coded all final follow-up ages that 
occurred after the 14th birthday as 14 years, whereas the population-based approach coded 
all final follow-up ages that occurred after the 17th birthday as 17 years.
RESULTS
The sample distribution by Muscular Dystrophy Surveillance, Tracking, and Research 
Network (MD STARnet) site showed a higher number of dystrophinopathy cases from AZ 
(22%), CO (22%), and GA (27%), with lower but approximately equal numbers from IA 
(14%) and wNY (13%) (data not shown). Cases were also predominantly non-Hispanic 
white (66%), followed by Hispanic (21%) and other race/ethnicity (13%), and their average 
age at last follow-up abstraction averaged 15 years 6 months (min, max = 1 – 29 years) (data 
not shown). For the total sample of all affected males (n=857), nearly one-half had at least 
one documented neurobehavioral concern (Table 1). Behavior problems (26%) were most 
frequently documented, followed by ADHD (18%) and depressed mood (17%). The oldest 
affected male subsample showed similar distributions as those for the total sample of males. 
Finally, analysis of the subsample of oldest males in the family who were at least 17 years of 
age at the time of last follow-up abstraction showed a higher frequency for depressed mood 
(31%) but lower frequencies for behavior problems (21%) and ADHD (18%).
Due to the similarity of frequency estimates across the total and oldest affected male 
samples, the remainder of findings are from analyses restricted to the latter subsample to 
avoid shared non-genetic factors (e.g., increased monitoring by caregivers or treating 
physicians of younger affected siblings due to clinical presentation and treatments received 
by older affected sibling) that may contribute to neurobehavioral concerns or treatments 
received. In this subsample of 765 males, 29% (n=225) had one recorded neurobehavioral 
concern, 13% (n=97) had two, and 3% (n=24) had all three (data not shown). On average, 
first concerns about ADHD and behavior problems occurred around age 8 years (SD=3 and 
4, respectively; min, max=3, 18 and 2, 27, respectively), and first concerns about depressed 
mood occurred around age 13 years (SD=4; min, max=4, 27) (data not shown). Among all 
oldest affected males, 414 (54%) used corticosteroids, 564 (74%) used a mobility device at 
least part-time, and 208 (27%) had used a respiratory support device (data not shown). On 
average, corticosteroids were initiated at approximately 7 years of age (SD=3; min, max=2, 
25); use of mobility and respiratory support devices was initiated at approximately 9 (SD=3; 
min, max=3, 24) and 16 years of age (SD=4; min, max=6, 26), respectively (data not shown).
Of the 346 cases with at least one recorded neurobehavioral concern, 238 (69%) received 
some form of mental health intervention (Table 2). Of those, 88 (25%) received 
neuropsychiatric medication only, 58 (17%) participated in counseling only, and 92 (27%) 
received both counseling and medication. Use of mental health interventions varied by type 
of neurobehavioral concern (Table 2); a low proportion (29%) of males with behavior 
problems only were prescribed neuropsychiatric medication. Conversely, higher proportions 
of males with ADHD only (52%) or depressed mood only (63%) were prescribed 
medication; stimulants were the most commonly prescribed for ADHD and antidepressants 
were most commonly prescribed for depressed mood. Counseling was least likely to be 
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recommended for those with ADHD only (57%). Counseling was recommended but not 
started for 12 males with ADHD only (6 were also prescribed medication), 25 with behavior 
problems only (5 were also prescribed medication), 20 with depressed mood only (14 were 
also prescribed medication), and 23 with a combination of two or more concerns (15 were 
also prescribed medication) (data not shown). The reasons why counseling was not initiated 
by the families were not indicated. Finally, the group with the lowest frequency of any 
mental health intervention was behavior problems only, for whom 56% had no documented 
intervention. Most cases (>80%) with depressed mood only or combinations of 
neurobehavioral concerns had the highest frequency of any mental health intervention.
Kaplan-Meier survival curves, estimated through age 29 years, showed cumulative 
probabilities of 23% for ADHD, 43% for behavior problems, and 51% for depressed mood 
(Table 3, and see Supplemental Digital Content, Figure 1, which shows estimates from 
Kaplan-Meier results for each neurobehavioral concern). The cumulative probabilities 
estimated from the Kaplan-Meier method were slightly higher than the observed frequencies 
for ADHD (23% vs 19%, respectively), but substantively higher than those for behavior 
problems (43% vs 26%, respectively) and depressed mood (51% vs 19%, respectively).
Cox regression analyses showed the hazard of ADHD was increased for corticosteroid users 
compared to non-users, but the crude HR was not statistically significantly different from 
1.0; conversely, a non-significant reduced hazard of ADHD was found for use of a mobility 
device (Table 4). The crude HRs were significantly larger than 1.0 for risk of behavior 
problems, with hazards 2.4 times higher during years in which corticosteroids were used and 
53% higher during years in which a mobility device was used (Table 4). The crude HR for 
the association between depressed mood and corticosteroids was found to be different from 
1.0, but not statistically significant; however, the hazard of depressed mood was 3.5 times 
more likely during years in which a mobility device was used. Adjusting for MD STARnet 
site as a fixed factor in the cox regression analyses did not substantively change the HRs and 
their statistical conclusion (data not shown).
Comparative Analyses
The cumulative probability estimates from the comparative analyses for the age of risk 
sample, which recoded maximum follow-up ages to disorder-specific ages, were similar to 
the estimates from the original sample for ADHD (22% vs 23%), but lower for behavior 
problems (28% vs 43%) and depressed mood (30% vs 51%) (Table 1 Supplemental Digital 
Content, and Figure 2 Supplemental Digital Content, which show Kaplan-Meier results for 
analysis of the age recoded samples). The results for the population-based recoded samples, 
which recoded maximum follow-up ages to 17 years for all outcomes, were similar to the 
age of risk recoded samples with a slight increase in the cumulative probability for behavior 
problems (30% vs. 28%) and a slight decrease for depressed mood (25% vs. 30%).
The conclusions from the Cox Regression analyses of the age-recoded analytic samples 
were similar to those from the original sample of oldest affected males. The HRs for ADHD 
remained statistically non-significant for use of corticosteroids (see Supplemental Digital 
Content, Figure 3, which shows crude hazard ratios for associations between corticosteroids 
and neurobehavioral concerns for age recoded analytic samples) or a mobility device (see 
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Supplemental Digital Content, Figure 4, which shows crude hazard ratios for associations 
between mobility device use and neurobehavioral concerns for age-recoded analytic 
samples). HRs for behavior problems calculated from each analytic sample did not change 
in magnitude from those of the previous sample and remained statistically significant. 
Finally, the magnitude of the HR for the associations between depressed mood and 
corticosteroid use in the population-based sample increased in magnitude and reached 
statistical significance, and the HR for use of a mobility aid increased in magnitude and 
retained significance.
DISCUSSION
Our study reports on the frequencies of ADHD, behavior problems, and depressed mood 
documented in the medical records of males with childhood-onset dystrophinopathies 
identified by the population-based Muscular Dystrophy Surveillance, Tracking, and 
Research Network (MD STARnet).22,25 Nearly one-half of the total sample had at least one 
of these three neurobehavioral concerns. Behavior problems were most frequently recorded, 
followed by ADHD and depressed mood. Compared to population estimates among males 
age 9–16 years, our observed frequency of behavior problems (26%) was similar to 
published estimates (30%).26 In contrast, our observed frequencies for ADHD (19% vs 
~8%)27–30 and depressed mood (19% vs 7%-13%)26,27 were nearly three times higher than 
population estimates.
Of those studies that reported on neurobehavioral concerns among individuals with a 
dystrophinopathy, our observed frequency of ADHD was higher compared to a study that 
used parent-reported physician diagnoses (12%, ages 5–18 years)8 but lower than studies 
that conducted formal ADHD evaluations (32%, ages 4–16 years)6,31 or relied on parent 
report of symptoms (50–62%, ages 8–15).9,13 Study differences were also found for the 
frequency of behavior problems from those that relied on parent reports on behavior 
checklists (e.g, Child Behavior Checklist, Strengths and Difficulties Questionnaire) with 
higher frequencies of behavior problems (>40%) than our observed estimate of 26%.11,13 
These checklists may include a broad range of behaviors that may not have been identified 
through medical record review, thereby resulting in higher reported frequencies. Similarly, 
comparisons with studies of the frequency of depressed mood showed variability by 
methods with reported frequencies ranging from no evidence of depression from parent-
report13,15 or self-report,9,20 to a frequency of 52% (ages 2–17) from a study that observed 
mood.14
Our examination of mental health interventions showed variability in treatment approaches 
by type of neurobehavioral concern. As expected, ADHD only was most often treated with 
psychostimulants, whereas depressed mood only was treated with antidepressants. The 
frequency of medications prescribed for the treatment of ADHD and depressed mood is 
consistent with that reported by Banihani et al.31 Behavior problems only had the lowest 
frequencies for both intervention modes. Concomitant treatment with medication and 
counseling was most common among those with more than one neurobehavioral concern 
and least frequent among those with ADHD or behavior problems only. As with care 
recommendations for the management of the physical morbidities of dystrophinopathy, 
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further development and evaluation of evidence-based treatments of neurobehavioral 
concerns among individuals with childhood-onset dystrophinopathies is needed.
Our use of longitudinal data allowed analysis of time-ordered associations between 
neurobehavioral concerns and use of corticosteroids or a mobility device. We showed a 
statistically significant higher risk of behavior problems among corticosteroid users, which 
is consistent with clinical observations, but inconsistent with previous studies that showed 
no association.11,15,19 Our findings that corticosteroid use did not significantly increase the 
risk for ADHD is consistent with previous cross-sectional studies that also failed to show 
significant associations between steroid use and ADHD.6,11,13,15 The absence of a 
significant association suggests that ADHD may be part of the dystrophinopathy phenotype 
and, regardless of corticosteroid use, may reflect how deficient dystrophin production in the 
brain contributes to attentional deficits in this population.4–6,16,32 We also observed that use 
of a wheelchair or scooter at least part-time was associated with increased risk of behavior 
problems and depressed mood, but not ADHD. Mixed findings have been reported for 
associations between declines in mobility, as documented by mobility device use in this 
study, and neurobehavioral concerns. A small study of males with DMD failed to find 
significant associations between parent-reported behavior problems and indicators of clinical 
severity (e.g., muscle wasting, absence of independent ambulation)13. In contrast, other 
studies have reported a role of declining mobility on behavioral and emotional 
adaptation11,15,18,19. These findings suggest monitoring of specific neurobehavioral 
concerns may differ by treatments implemented and stage of disease progression.
We used multiple analytical approaches to evaluate frequencies of neurobehavioral concerns 
among males with a dystrophinopathy. These approaches included use of time-to-event 
analyses (i.e., Kaplan-Meier method) and comparative analyses that employed multiple 
sample definitions to account for age of risk for each outcome and, where possible, allowed 
comparison with samples from general population studies. We found relatively stable 
observed and cumulative probabilities across all samples and analytic methods for ADHD 
(18–23%), which was not surprising because DSM-IV diagnostic criteria require symptom 
onset prior to age 7 years and the majority (91%) of cases were past this age at last follow-
up. The behavior problems we examined (e.g., anger, conduct disorder, aggressive behavior) 
are also generally characterized as childhood-adolescent disorders but showed greater 
variability across samples and analytic methods, with observed frequencies ranging from 
21–26%, and cumulative probabilities ranging from 28–43%. Our highest probability 
observed for occurrence of behavior problems was from Kaplan-Meier estimates for oldest 
affected males (43%), and the lowest were from our samples that restricted follow-up to 
mid- to late-adolescence (28–30%). This variability in estimates suggests that the occurrence 
of behavior problems in childhood-onset dystrophinopathy may extend beyond the expected 
upper age limit generally reported for disruptive behaviors in general population 
studies.23,29 The extended age of onset could also be attributed, in part, to the role of 
corticosteroids and response to disease progression (e.g., frustration with decreasing 
mobility or increasing social isolation), as supported by the significant associations between 
these factors and onset of behavior problems. Finally, frequencies associated with depressed 
mood also varied by our sample types and analytic methods. The observed frequency for 
depressed mood was higher among cases who were at least age 17 years (31%) compared to 
Conway et al. Page 9













our sample of oldest affected males only (17%); conversely, our age recoded samples 
showed lower cumulative probabilities when we restricted the sample to early or late 
adolescence (30% and 25%, respectively). These findings are consistent with a late-onset 
disorder, such as depression, and highlight the potential underestimation of risk for 
depressed mood in dystrophinopathies if the sample does not include older patients.
Our study has many methodological and analytical advantages compared to previous cross-
sectional studies of patients with dystrophinopathy. The MD STARnet provides the largest 
population-based sample of individuals with childhood-onset dystrophinopathies in the 
United States. The sample size permitted use of complex analytic methods to evaluate the 
lifetime risk of neurobehavioral concerns, specifically, the use of time-to-event analytic 
methods (i.e., Kaplan Meier method). Our use of longitudinal surveillance of both 
neurobehavioral concerns and medical treatments and supportive devices also permitted 
evaluation of time-ordered associations that might not be possible with a cross-sectional 
study design. Furthermore, our reliance on medical record review may have minimized the 
impact of recall bias on frequency estimates generated from cross-sectional studies33 and 
permitted examination of prescribed mental health interventions used to treat 
neurobehavioral concerns in this population.
Despite the methodological and analytical advantages, our findings need to be interpreted 
with caution. The MD STARnet identifies and tracks cases with childhood-onset 
dystrophinopathies within a defined geographical areas, potentially limiting generalization 
to the entire United States population.22 Our analyses did not distinguish between DMD and 
BMD but rather focused on the inclusive dystrophinopathy diagnosis. We recognize that 
ignoring this distinction may affect extrapolation of expected frequencies of specific 
neurobehavioral concerns within each dystrophinopathy subtype due to variability in 
dystrophin deficiency.34 However, there should be little influence on the association 
analyses between our indicators of disease severity and neurobehavioral concerns studied. 
Clinical data were predominantly abstracted from neuromuscular medical records, which 
may have led to an underestimation of the frequency of concerns not listed in the reviewed 
records and the absence of results from formal neuropsychiatric evaluation and diagnosis. 
Furthermore, additional neurobehavioral concerns reported in previous studies of 
dystrophinopathy (e.g., autism spectrum disorder, cognitive functioning) were not analyzed 
due to inconsistent documentation in the medical records and lack of access to requisite 
diagnostic test results (e.g., cognitive function evaluations). Our data collection also did not 
allow determination of whether neuropsychiatric medications were prescribed for a 
neurobehavioral concern or for an alternative co-morbid condition. However, the patterns of 
prescribed medications within the neurobehavioral categories provide us with limited 
external validity to the categories of concerns we defined from review of medical records. 
Another limitation is the quality of the event dates recorded. Although we conducted careful 
review of these dates, they may not accurately reflect the actual onset of a neurobehavioral 
concern, as time will lapse between the initial observation by the caregiver and reports to a 
healthcare provider; thus, there may be some misclassification in the time ordering of 
events. In addition, the neurobehavioral concerns studied were treated analytically as 
independent events, when the true nature of analyzed, and unanalyzed (e.g., autism spectrum 
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disorder), neurobehavioral concerns may represent a continuum of behaviors (e.g., ADHD 
and behavior problems fall within the DSM-IV attentive and disruptive behaviors axis) or 
may be temporally related (e.g., behavior problems increases likelihood of experienced 
depressed mood). Lastly, detection and documentation of neurobehavioral concerns may not 
be standard across clinics or treating healthcare providers and may reflect caregiver report 
rather than formal diagnoses; thus, the data recorded in the medical record could reflect 
differences in health care provision or reporting of these concerns by caregivers or patients.
In conclusion, our findings identified neurobehavioral concerns as common co-morbidities 
of childhood-onset dystrophinopathies. Our findings suggest that use of corticosteroids is 
associated with an increased risk of behavior problems, ADHD might be a part of the 
dystrophinopathy neurocognitive phenotype, and the risk of depressed mood increases with 
disease severity. Considering these findings, and consistent with the recommendations of the 
2010 DMD Care Considerations,18 the use of brief screening tools in the neuromuscular 
office, referrals for standardized evaluation and monitoring of neurobehavioral concerns, 
and where appropriate, provision of pharmacological interventions and improved access to 
psychosocial counseling should be encouraged in this patient population. Future studies 
should continue to explore biological etiologies in order to promote early identification and 
determine appropriate interventions.
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Table 1
Frequencies and percentages of neurobehavioral concerns among males with dystrophinopathies from the 







Neurobehavioral concern1 n % n % n %
Sample sizes 857 - 765 - 309 -
None 482 56 419 55 152 49
ADHD 156 18 146 19 56 18
Behavior problems 223 26 202 26 66 21
Depressed mood 150 17 143 19 97 31
ADHD=attention deficit/hyperactivity disorder.
1
Males may have more than one documented neurobehavioral concern, thus, the categories are not mutually exclusive, and the total % may exceed 
100%.
2
Included all affected males (older and younger siblings) from a family. Average age of younger affected siblings (n=92; Mean=13.47, Standard 
Deviation=5.87; minimum, maximum=1, 26).
3
All males who were at least 17 years of age at last follow-up clinic visit.
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Table 2
Types of mental health interventions by type of neurobehavioral concern1 among oldest affected males with 












Interventions n (%) n (%) n (%) n (%)
Totals 63 95 67 121
Neuropsychiatric Medications2
  Any medication 33
(52)
28 (29) 42 (63) 77 (64)
  Antidepressants 7 (11) 11 (12) 37 (55) 51 (42)
  Anticonvulsants 3 (5) 10 (11) 10 (15) 19 (16)
  Anxiolytics 7 (11) 6 (6) 11 (16) 23 (19)
  Antipsychotics 2 (3) 7 (7) 1 (1) 10 (8)
  Stimulants 29
(46)
8 (8) 0 (0) 42 (35)
Counseling
  Not recommended 36
(57)
41 (43) 18 (27) 21 (17)
  Recommended not received 12
(19)
25 (26) 20 (30) 23 (19)
  Received 15
(24)
29 (31) 29 (43) 77 (64)
Neuropsychiatric Medication
or Counseling Received
  None 24
(38)
53 (56) 12 (18) 19 (16)
  Medication only 24
(38)
13 (14) 26 (39) 25 (21)
  Counseling only 6 (10) 14 (15) 13 (19) 25 (21)
  Both medication and
counseling
9 (14) 15 (16) 16 (24) 52 (43)
ADHD=attention deficit/hyperactivity disorder.
1
The calculation of ‘ADHD only’, ‘Behavior problems only’, ‘Depressed mood only’, and ‘Multiple concerns’ used all three subtypes of 
neurobehavioral concerns to classify.
2
Males may have been prescribed more than one neuropsychiatric medication.
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Table 3
Kaplan-Meier results for neurobehavioral concerns among oldest affected males with dystrophinopathies from 










ADHD 146 619 (81) 77 23
Behavior problems 202 563 (74) 57 43
Depressed mood 143 622 (81) 49 51
ADHD=attention deficit/hyperactivity disorder.
1
No documentation of neurobehavioral concern at last health encounter
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Table 4
Crude hazard ratios (cHR)s and 95% confidence intervals (CI) from Cox regression with time dependent 
covariates predicting neurobehavioral concerns among oldest affected males with dystrophinopathies from the 
Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), 1982–2011 (n=765)
Models cHR 95% CI
ADHD
  Corticosteroids1 1.31 0.92–1.88
  Mobility assistive device 0.85 0.55–1.30
Behavior problems
  Corticosteroids1 2.35 1.75–3.16
  Mobility assistive device 1.53 1.06–2.21
Depressed mood
  Corticosteroids1 1.33 0.94–1.88
  Mobility assistive device 3.53 2.13–5.85
ADHD=attention deficit/hyperactivity disorder.
1
Corticosteroid use defined as at least one day of use within a year.
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